Business Wire

MD-IPROOV

13.1.2021 01:02:32 CET | Business Wire | Press release

Share
Covid-19 Passport from iProov and Mvine Moves Into Trial Phase

Mvine and iProov announce today their design for a simple, secure and widely recognized Covid-19 immunity and vaccination passport will now move into live testing. The Mvine-iProov passport enables a person’s test result or vaccination status to be registered and proved without disclosing their identity, and without the need for extensive new infrastructure.

With additional backing from Innovate UK, which initially funded the development of a successful working prototype, the Mvine-iProov passport will now be tested by Directors of Public Health within the National Health Service (NHS) in the UK. Mvine and iProov aim to complete two trials by 31 March 2021, giving Directors of Public Health across the country the confidence to deploy the passport at scale to benefit their local areas.

Crucially, the Mvine-iProov passport can be plugged into the NHS’ existing infrastructure, enabling it to meet the specific needs of local Directors of Public Health and any overarching national requirements. This flexibility ensures that areas in different tiers or levels of vaccination rollout can set appropriate policies and enforce them with confidence.

The Mvine-iProov passport has been developed quickly and cost-efficiently, with a total £75,000 investment from Innovate UK following a call for ideas in April 2020. It is expected this investment in UK innovation will help businesses and employees return to work, and enable families and friends to reconnect, more quickly and more responsibly than would otherwise be possible.

Frank Joshi, Director at Mvine, said: “Without the need for an extensive new infrastructure, the Directors of Public Health will learn how our innovation is used to promote public health and protect citizen privacy. Unlike some other digital solutions for Covid-19, this technology reduces the burden on frontline services and cost-effectively assures a secure and safe way to enable the return to work, return to school and return to the kind of life that people want to lead .”

Andrew Bud, CEO at iProov, said: “Ensuring consumer trust, security and privacy is essential to the success of projects in this space. iProov enables all three. Our Genuine Presence Assurance technology secures the link between the citizen and Mvine’s test status solution in this project, which we think can make an important contribution to forming the national response to the COVID-19 crisis.”

ENDS

About iProov

Founded in 2012, iProov is the world leader in online facial biometric authentication, working with governments, banks and other enterprises to remotely verify customer identity. Used for onboarding and authentication, customers include the U.S. Department of Homeland Security, the UK Home Office, the UK National Health Service (NHS), GovTech Singapore, Eurostar, Rabobank, ING, and others. iProov’s unique patented technology provides Genuine Presence Assurance, ensuring that an online customer is the right person, a real person, and authenticating right now. This protects against spoof attacks from photos, videos, masks and the emerging threat of deepfakes. iProov was recognized as the 5th fastest growing technology company in the UK in the Deloitte 2020 UK Technology Fast 50 and was also named a Gartner Cool Vendor 2020 in Identity Access Management & Fraud Detection. For more information, please see www.iproov.com

About Mvine

Mvine Limited is a British deep tech company delivering next generation platforms that power the digital economy. It is perhaps best known for its work in providing cyber-secure collaboration portals, in use in the financial services sector as virtual deal rooms and in other industries as procurement portals and as diversity/equality portals. The company has also pursued identity management and its technology is in use in the telecoms sector for federated authentication and in other industries for single sign on identity, authentication and authorization. www.mvine.com

About Innovate UK

Innovate UK drives productivity and economic growth by supporting businesses to develop and realise the potential of new ideas. We connect businesses to the partners, customers and investors that can help them turn ideas into commercially successful products and services and business growth. We fund business and research collaborations to accelerate innovation and drive business investment into R&D. Our support is available to businesses across all economic sectors, value chains and UK regions. Innovate UK is part of UK Research and Innovation. For more information visit www.innovateuk.ukri.org

Fact Checking

The UK government announcement on 20 May 2020 to expand the funding envelope from £20 million to £40 million meant 800 funding awards could be made. The original announcement was made on 3 April 2020 by BEIS, Innovate UK and Amanda Solloway MP. The competition opened Friday 3 April 2020 and closed Friday 17 April 2020.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release

Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye